Hua-Wei Yi

Hua-Wei Yi

Auto-generated profile, based on publicly available information

Hua-Wei Yi

Department of Laboratory Medicine, the First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JLJun-Fei Lu
Jun-Fei Lu
XZXin-Ran Zhang
Xin-Ran Zhang
YLYe Liu
Ye Liu
CZChang-Li Zhang
Chang-Li Zhang
LWLi Wang
Li Wang
HYHua-Wei Yi
Hua-Wei Yi
Colorectal cancer (CRC), a gastrointestinal malignancy with persistently high global incidence and mortality rates, urgently demands more efficient early screening strategies and precision therapeutic approaches. Nucleic acid aptamers, recognized as “chemical antibodies”, have emerged as a research hotspot in CRC diagnosis and treatment due to their high target specificity, flexible chemical modifiability, and cost-effective synthesis. In diagnostic applications, integrating aptamers with fluorescence, surface-enhanced Raman scattering (SERS), and electrochemical biosensors, along with functionalized nanomaterials such as quantum dots, gold nanoparticles, and graphene, has enabled ultrasensitive detection of biomarkers including carcinoembryonic antigen (CEA), miRNAs, exosomes, and circulating tumor cells (CTCs). In the therapeutic arena, we highlight aptamer-decorated lipidic, polymeric, and inorganic nanocarrier systems for targeted drug delivery featuring pH/glutathione (GSH)-responsive release mechanisms, and we review emerging immunotherapeutic regimens that employ PD-1/PD-L1 blocking aptamers alone or in combination with immunomodulatory agents or small activating RNAs. Finally, current challenges in aptamer applications—such as in vivo stability, targeted delivery efficiency, large-scale production, and clinical translation—are critically discussed. Future perspectives propose AI-assisted intelligent aptamer design, multi-omics-integrated diagnostic and therapeutic platforms, and standardized clinical trials to advance the implementation of nucleic acid aptamers in CRC precision medicine.

1 July 2025 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
PTPeng-Peng Tian
Peng-Peng Tian
HYHui Yang
Hui Yang
TWTian Wang
Tian Wang
LWLi Wang
Li Wang
MDMeng-Yao Du
Meng-Yao Du
HYHua-Wei Yi
Hua-Wei Yi
Purpose: This study aims to evaluate the accuracy of EUCAST rapid antimicrobial susceptibility testing (RAST) for Gram-negative bacteria directly from positive blood cultures, comparing it with short-term incubation (5– 7 hours) and conventional broth microdilution methods. Methods: A total of 139 Gram-negative isolates were tested. RAST results were assessed at 4 h, 6 h against minimal inhibitory concentration results using the short-term incubation (5– 7 h) method, while at 16– 20 h, the RAST results were compared to conventional method. For those with interpretable results, CLSI M52 was used to define cutoffs for equivalence in antimicrobial susceptibility testing. Results: Among all isolates, 80.6% (112/139) were successfully interpreted based on EUCAST RAST breakpoints, including Escherichia coli (81), Klebsiella pneumoniae complex (17), Pseudomonas aeruginosa (10) and Acinetobacter baumannii (4). The overall category agreements for all tested antibiotics were 98.9%, 99.5%, and 99.7% at 4, 6, and 16– 20 hours, respectively, for E. coli, and 100% for K. pneumoniae, P. aeruginosa, and A. baumannii. The area of technical uncertainty rate significantly decreased over time, from 9.1% at 4 hours to 3.1% at 16– 20 hours (p < 0.05). The method effectively identified extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant bacteria, demonstrating performance comparable to the BD system. Additionally, results for other Enterobacterales could be interpreted using the RAST breakpoints for E. coli. The integration of RAST into routine workflows provides rapid and accurate results without incurring additional costs or labor. Conclusion: RAST is a reliable and cost-effective method for testing Gram-negative bacteria directly from blood cultures, significantly reducing turnaround time. Utilizing RAST at various reading times (6 hours and 16– 20 hours) optimizes clinical workflows, enhances antimicrobial stewardship, and improves patient outcomes.

15 July 2025 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Open access
MCMeng-Yang Cai
Meng-Yang Cai
HYHua-Wei Yi
Hua-Wei Yi
YCYa-Qian Cai
Ya-Qian Cai
RFRui-Min Feng
Rui-Min Feng
YLYe Liu
Ye Liu
XWXian-Mo Wang
Xian-Mo Wang
Acute respiratory infections (ARIs) are a leading cause of pediatric morbidity and mortality globally, yet comprehensive pathogen epidemiology in children remains understudied. This study aimed to characterize the pathogen profiles, co-infection patterns, and epidemiological trends of pediatric ARIs in Xiantao, China, using targeted next-generation sequencing (tNGS). A retrospective analysis was conducted on 4,330 children hospitalized with ARIs from May 2022 to September 2023. Oropharyngeal swab specimens were tested by tNGS for 96 pathogens via ultra-multiplex PCR and high-throughput sequencing. Pathogens were detected in 99.3 % (4,298/4,330) of cases, with multi-pathogen co-infections in 88.7 % (3811/4298) of samples, including dual (26.1 %), triple (28.2 %), and ≥quadruple pathogens (34.4 %), demonstrating high co-infection complexity. Bacterial pathogens (57.7 %) exceeded viral (35.7 %) and Mycoplasma/ Chlamydial (6.6 %). Age-stratified analysis revealed significant variability in 37 pathogens (p < 0.05), with incidence inversely correlated to age. Seasonal peaks occurred in spring (March-May) and early summer (June), driven first by bacterial then viral agents. Pneumonia (57.8 %, 2,407/4,162) and acute upper respiratory infections (24.1 %, 1,005/4,162) were the most frequent clinical diagnoses. tNGS provides rapid, comprehensive pathogen identification in pediatric ARIs while uncovering intricate co-infection patterns. The findings highlight the importance of age-specific and seasonal considerations in managing respiratory infections, and suggest that tNGS has the potential to provide information useful for clinical decision-making, reduce antibiotic misuse, and improve pediatric outcomes-although these advantages await confirmation in future studies.